This study is conducted in Japan of vonicog alfa (rVWF) used to treat pediatric participants with Von Willebrand Disease (vWD).
The main aim of the study is to evaluate adverse drug reaction and effectiveness of vonicog alfa (rVWF).
During the study, pediatric participants with vWD will be administered with rVWF under routine normal practice. The investigators will evaluate adverse events due to rVWF for 1 year from the start of drug administration.
The study sponsor will not be involved in how the participants are administered but will be recorded what happens during the study.
Under 18 years old with vWD.
Participants who are treated with rVWF for the purpose of hemostatic treatment and management during bleeding episodes or perioperative periods.
Participants who have prescription or administration after the approval date of rVWF for pediatric use in Japan.
None
The population of this study are all participants who meet the inclusion/exclusion criteria.
Cohort
Prospective
vonicog alfa (rVWF)
DrugrVWF administered by intravenous injection.
Number of Participants who Experience at Least One Adverse Drug Reactions (ADRs)
Adverse Event (AE) refers to any undesirable medical occurrence in a patient administered a drug, regardless of causal relationship. This includes any unfavorable or unintended sign (including abnormal laboratory findings), symptom, or disease occurring during administration, regardless of causal relationship. Adverse drug reaction (ADR) refers to AE related to administered drug.
Hemostatic Efficacy Assessed by Hemostatic Efficacy Rating Scale
Hemostatic efficacy for bleeding episodes will be assessed by a predefined 4-point rating scale (Excellent, Good, Moderate, None).
Hemostatic Efficacy during Perioperative Periods Assessed by Hemostatic Efficacy Rating Scale
Hemostatic efficacy during perioperative periods will be assessed by a predefined 4-point rating scale (Excellent, Good, Moderate, None).
Number of Infusions per Bleeding Episode
Number of Infusions during Perioperative Periods
